Rigel Pharmaceuticals, Inc. (RIGL)
Makes medicines that treat blood cancers and immune disorders.
$38.50+0.03%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+75.7%
The outlook
RIGL is trading at $38.50 with a Buy consensus from analysts. The stock sits solidly above both its 50- and 200-day moving averages, roughly midway through its 52-week range. Analyst price targets average around 43% above the current price, and the trailing P/E of 1.9 reflects a low valuation multiple.
What’s behind the score
Analyst consensusBuy — 1.8 avg of 5 analysts
Price trendAbove its 50- & 200-day averages
52-week range58% of the way from its 52-week low to high
Price targetAvg target +43% vs current price
Analyst price target
~12-month · 5 analysts$55.20average target+43.4% vs now
Now $38.50
Low $40.00High $81.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$712.3M
52-wk high
$52.24
52-wk low
$19.51
50-day avg
$34.95
200-day avg
$34.77
Trailing P/E
1.9